All In Biotech

Drug Trial Radar · NCT03362281

Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

Efficacy and Safety of Intravenous IIaprazole for Peptic Ulcer Bleeding: A Randomized, Double-Blind, Omeprazole-Controlled, Multicenter, and Phase 3 Trail in China

Last checked: Nov 19, 2026Latest source record: Dec 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

540

Actual

Start

Oct 2014

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Sponsor type
Industry
First posted
Dec 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase study is to confirm the efficacy and safety by compare ilaprazole and omeprazole in the treatment and prevention of peptic ulcer bleeding. Patients with endoscopically diagnosed peptic ulcer bleeding were enrolled in a multi-center, stratified randomized, non-inferiority test, double-blind, parallel and positive-controlled trial. They were randomly assigned into two groups, ilaprazole and omeprazole, to be treated for up to 30 days. The primary endpoint was the hemostasis rate at the end of 72 hours. Secondary end points include ulcer staging changes within 72 hours, effective rate of hemostasis, hemostasis duration, average blood transfusion and rebleeding rate, etc.

Conditions

  • Peptic Ulcer Hemorrhage

Interventions

  • IlaprazoleDrug

    10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.

  • OmeprazoleDrug

    40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.

  • Ilaprazole tabletDrug

    Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day

  • amoxicillin and clarithromycinDrug

    The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the rate of hemostasisTime frame: 72 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.